{"id":"NCT01733758","sponsor":"GlaxoSmithKline","briefTitle":"A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-02","primaryCompletion":"2014-06","completion":"2015-02","firstPosted":"2012-11-27","resultsPosted":"2015-05-18","lastUpdate":"2016-09-22"},"enrollment":494,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Albiglutide 30 mg weekly","otherNames":[]},{"type":"DRUG","name":"Albiglutide 50 mg weekly","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Liraglutide 0.9 mg daily","otherNames":[]}],"arms":[{"label":"Albiglutide 30 mg weekly","type":"EXPERIMENTAL"},{"label":"Albiglutide 50 mg weekly","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Liraglutide 0.9 mg daily","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to examine the efficacy and safety of 2 dose levels of weekly subcutaneously injected albiglutide compared with placebo and an open label reference arm of daily subcutaneous injections of liraglutide, in Japanese subjects with Type 2 diabetes mellitus.","primaryOutcome":{"measure":"Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Placebo","deltaMin":0.25,"sd":0.068},{"arm":"Albiglutide 30 mg Weekly","deltaMin":-1.1,"sd":0.047},{"arm":"Albiglutide 50 mg Weekly","deltaMin":-1.3,"sd":0.049}],"pValues":[{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":74,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":77},"commonTop":["Nasopharyngitis","Constipation","Nausea","Hypoglycaemia","Diarrhoea"]}}